Suggested language and usage for tuberculosis communications
First edition
Accessed November 2017
Guidelines for social mobilization
TB and poverty; TB and children; TB and women; TB, migrants and refugees; TB and prisons
WHO/CDS/STB/2001.9
Original: English; Distribution: Limited
The Asia Pacific Observatory on Health Systems and Policies is a collaborative partnership which supports and promotes evidence-based health policy making in the Asia Pacific Region. Based in WHO’s Regional Office for South-East Asia, it brings together governments, international agencies, foundat...ions, civil society and the research community with the aim of linking systematic and scientific analysis of health systems in the Asia Pacific Region with the decision-makers who shape policy and practice.
more
Long-term planning for an adequate and safe supply of drinking-water should be set in the context of growing external uncertainties arising from changes in the climate and environment. The water safety plan (WSP) process offers a systematic framework to manage these risks by considering the implica...tions of climate variability and change.
more
Strengthening resilient agricultural livelihoods
Level 3 responses are activated in the most complex and challenging humanitarian emergencies, when the highest level of mobilization is required across the humanitarian system. Even before the conflict escalated, the country suffered high levels of p...overty, food insecurity, undernutrition and malnutrition, water shortages and land degradation. Yemenis are also facing armed conflict, displacement, risk of famine and disease outbreaks.
more
This manual provides information and guidance for individuals concerned with the mental health needs of children who experience major disasters. This background, training, and experience will vary and may include health and mental health professionals, professional and paraprofessional social servic...e personnel, school and daycare personnel, clergy, volunteers, and parents.
more
In an environment of stagnant donor funding and increasing private sector investment in low- and middle-income countries, actors in both the public and private sectors are increasingly interested in using blended finance approaches to catalyze new funding for global health and achieve health outcome...s. As USAID moves towards greater engagement with the private sector, blended finance will be an important component to help achieve development objectives.
Accessed 19th May 2019.
more
Antimicrobial resistance (AMR) is a complex issue of global concern. AMR is not simply a problem of medical science being beaten by nature; human action and perverse incentives play a major role in its development. The misuse of antibiotics in the medical, veterinary and agricultural sectors, which ...include the inappropriate prescribing of antibiotics, their overuse in the livestock sector, and insufficient hygiene practices in hospital, all contribute to the rise of AMR.
more
Antimicrobial resistance (AMR) is an important public health concern shared by developed and developing countries. In developing countries the burden of infectious diseases is greater and exacerbated by limited access to, and availability and affordability of, antimicrobials required to treat infect...ions caused by AMR organisms. With drugs not listed on the essential drugs list (EDL), problems of increased morbidity, costs of extended hospitalisation and mortality are extremely serious. The problem of susceptibility to and spread of infections caused by multidrug-resistant (MDR) infectious agents is fuelled by factors such as limited access to clean water and sanitation to ensure personal hygiene, malnutrition, and the HIV/TB epidemic.
more
The Millennium Development Goals (MDGs) showed
that global commitment and collective action
could significantly reduce the disease burdens of
three deadly communicable diseases: HIV/AIDS,
tuberculosis (TB) and malaria. The MDGs helped
focus efforts on these three deadly diseases
and leveraged ...disease-specific programmes and
financing, thus achieving significant progress.
more
In 2016, the risk of premature mortality1 from noncommunicable diseases (NCDs) in Ethiopia was 18.3%. The economic costs of NCDs are significant and are due principally to their impact on the non-health sector (reduced workforce and productivity). In this study, it is estimated that NCDs cost Ethiop...ia at least 31.3 billion birr (US$ 1.1 billion) per year, equivalent to 1.8% of the gross domestic product (GDP). Less than 15% of the costs are for health care.
more
Every year, an estimated 15 million babies are born preterm – before 37 weeks of pregnancy. That is more than 1 in 10 live births. Approximately 1 million children die each year worldwide due to complications from their early birth. Those that survive often face a lifetime of ill-health including ...disability, learning difficulties, and visual and hearing problems.
Half of the babies born at or below 32 weeks (2 months early) die in low-income settings, due to a lack of feasible, cost-effective care, such as warmth, breastfeeding support, and basic care for infections and breathing difficulties. In high-income countries, almost all these babies survive.
more
Las recomendaciones contenidas en este módulo son un componente de las directrices unificadas de la OMS sobre la tuberculosis (TB) y están destinadas principalmente para el uso de los programas nacionales de control de la tuberculosis, los organismos de salud pública y otros interesados clave que... participan en la planificación, ejecución y seguimiento de las actividades de gestión programática de la TB farmacorresistente. El objetivo esta actualización es proporcionar información basada en la evidencia sobre determinadas áreas críticas que ayude a fundamentar el uso de nuevos esquemas totalmente orales y la posible ampliación de la ficha técnica de los nuevos medicamentos contra la TB. Los interesados directos podrán distinguir entre las recomendaciones anteriores que siguen siendo válidas, las que se han actualizado y las que se han elaborado recientemente sobre la base de estudios adicionales, teniendo en cuenta la gama de beneficios conocidos y posibles daños, los ejercicios de modelización y otros datos para fundamentar el proceso de toma de decisiones.
more
J Pharm Pharm Sci (www.cspsCanada.org) 16(3) 441 - 455, 2013